SABCS: PD 0332991 + letrozole studied in ER+ breast cancer

December 5, 2012
SABCS: PD 0332991 + letrozole studied in ER+ breast cancer
For women with estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast cancer, the investigational agent PD 0332991 plus letrozole improves progression-free survival versus letrozole alone; and fulvestrant 500 mg correlates with improved survival versus the 250-mg dose, according to two studies presented at the annual San Antonio Breast Cancer Symposium, held from Dec. 4 to 8.

(HealthDay)—For women with estrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer, the investigational agent PD 0332991 plus letrozole improves progression-free survival versus letrozole alone; and fulvestrant 500 mg correlates with improved survival versus the 250-mg dose, according to two studies presented at the annual San Antonio Breast Cancer Symposium, held from Dec. 4 to 8.

Richard S. Finn, M.D., from the University of California Los Angeles, and colleagues compared PD 0332991 plus letrozole versus alone for the first-line treatment of ER-positive/HER2-negative breast cancers in a two-part phase II study (66 , Part 1; 99 women with certain genomic alterations, Part 2). The researchers identified significantly improved median progression-free in the combination arm of the Part 1 group (hazard ratio [HR], 0.35). This significant improvement in median progression-free survival with the combination treatment continued to be observed in the 99 patients making up the Part 2 group (HR, 0.32).

In a second study, Angelo Di Leo, M.D., Ph.D., from the Hospital of Prato in Italy, and colleagues compared fulvestrant 500 mg (362 women) with 250 mg (374 women) in postmenopausal women with advanced ER-positive that had recurred or progressed with prior . In the follow-up analysis of this phase III trial, the researchers found that median overall survival was significantly improved for fulvestrant 500 mg versus fulvestrant 250 mg (26.4 versus 22.3 months; HR, 0.81; P = 0.016). No clinically important differences were seen in the serious adverse event profiles between the treatment groups.

"For those postmenopausal women with recurrent or progressing ER-positive locally advanced or for whom fulvestrant is the appropriate treatment choice, the standard of care is a 250-mg dose," Di Leo said in a statement. "Our results indicate that this should be modified to a 500-mg dose."

Several authors from the Finn study are employees of Pfizer, which is developing PD 0332991. One author from the Di Leo study disclosed financial ties to AstraZeneca, the manufacturer of fulvestrant.

Explore further: Anastrozole and fulvestrant combo better than single drug for metastatic breast cancer

More information: Press Release - Finn
Press Release - Di Leo
More Information

Related Stories

Anastrozole and fulvestrant combo better than single drug for metastatic breast cancer

August 1, 2012
Results of a SWOG clinical trial published August 2 in the New England Journal of Medicine show the combination of anastrozole and fulvestrant extended the median survival time of women with hormone receptor-positive metastatic ...

Anti-estrogen combo better than single drug for hormone-sensitive breast cancer

December 7, 2011
Post-menopausal women with hormone receptor-positive metastatic breast cancer may have a new treatment option that could lengthen their lives, according to results of a study by the SWOG clinical trials network that were ...

New hope for advanced post-menopausal breast cancer patients resistant to hormonal therapy

September 26, 2011
Results from a phase III clinical trial have shown that combining two existing cancer drugs to treat post-menopausal women with advanced breast cancer resistant to hormonal therapy significantly improves outcome. Researchers ...

Vandetanib doesn't up survival in non-small-cell lung cancer

March 2, 2012
(HealthDay) -- Vandetanib does not improve overall survival for patients who have received previous treatment for advanced non-small-cell lung cancer (NSCLC), according to a study published online Feb. 27 in the Journal of ...

Breast cancer recurrence defined by hormone receptor status

October 1, 2012
Human epidermal growth factor (HER2) positive breast cancers are often treated with the same therapy regardless of hormone receptor status. New research published in BioMed Central's open access journal Breast Cancer Research ...

ASCO: Continuing avastin with 2nd-line chemo ups survival

June 5, 2012
(HealthDay) -- Continuing use of bevacizumab (Avastin) in combination with second-line chemotherapy improves overall survival (OS) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC) who ...

Recommended for you

Stem cell vaccine immunizes lab mice against multiple cancers

February 15, 2018
Stanford University researchers report that injecting mice with inactivated induced pluripotent stem cells (iPSCs) launched a strong immune response against breast, lung, and skin cancers. The vaccine also prevented relapses ...

Induced pluripotent stem cells could serve as cancer vaccine, researchers say

February 15, 2018
Induced pluripotent stem cells, or iPS cells, are a keystone of regenerative medicine. Outside the body, they can be coaxed to become many different types of cells and tissues that can help repair damage due to trauma or ...

Team paves the way to the use of immunotherapy to treat aggressive colon tumors

February 15, 2018
In a short space of time, immunotherapy against cancer cells has become a powerful approach to treat cancers such as melanoma and lung cancer. However, to date, most colon tumours appeared to be unresponsive to this kind ...

Can our genes help predict how women respond to ovarian cancer treatment?

February 15, 2018
Research has identified gene variants that play a significant role in how women with ovarian cancer process chemotherapy.

First comparison of common breast cancer tests finds varied accuracy of predictions

February 15, 2018
Commercially-available prognostic breast cancer tests show significant variation in their abilities to predict disease recurrence, according to a study led by Queen Mary University of London of nearly 800 postmenopausal women.

Catching up to brain cancer: Researchers develop accurate model of how aggressive cancer cells move and spread

February 15, 2018
A brief chat at a Faculty Senate meeting put two University of Delaware researchers onto an idea that could be of great value to cancer researchers.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.